The United States healthcare system has experienced an expansion of private equity ownership. In new research, Theodosia Stavroulaki argues that private equity acquisitions risk harming healthcare by increasing prices, reducing quality of care, limiting access to care, and hurting the labor force.

Investors have poured billions into using artificial intelligence to discover new drugs, and 2026 is the first real test of whether AI-designed medicines actually helps patients. The boom has genuinely transformed the search for molecules — but that was never the costly, failure-prone part of making a medicine, and there AI has so far had little to add. Capital, and the public subsidies have not yet priced the difference, writes Michael A. Santoro.

In February, the Federal Trade Commission settled with pharmaceutical benefits manager (PBM) Express Scripts. The FTC had sued Express Scripts and two other large PBMs under the long dormant Section 5 of the FTC Act, which targets “unfair methods of competition.” The settlement suggests that the FTC may succeed in addressing the convoluted contracts between PBMs, drug manufacturers, health insurers, and employers that drive up drug prices for Americans. It also opens unchartered territory for antitrust enforcement and the limits of Section 5, argue Fiona Scott Morton and Mariah Smith.

In new research, Renuka Diwan, Paul Eliason, Riley League, Ryan C. McDevitt, James W. Roberts, and Jetson Leder-Luis investigate how Medicare’s shift to a competitive bidding system to reduce prices has inadvertently shifted market share to fraudulent suppliers.

The OxyContin epidemic had large demographic effects on communities in the United States. In new research, Carolina Arteaga, Victoria Barone, and Stephen Claassen find that Purdue Pharma’s marketing strategy targeted specific areas, causing college-educated residents to flee and increasing fertility rates among the most affected populations.

The EU’s constitutional framework and European Union Court of Justice’ case law have evolved since the European Union enacted the first Merger Guidelines in 2004. The revised Merger Guidelines should better engage with these developments and reflect the priority constitutional values and democracy now play in economic policy, writes Kati Cseres.

In a new working paper, Benjamin Verschuere and Angus Cameron argue that the wide dispersion in economists' forecasts for the impact of artificial intelligence on the economy stems from two gaps. The first is that estimates for growth, jobs, and prices are each built in isolation, with no single framework to reconcile them. The second is that models fixate on AI’s current capabilities, rather than on how fast it spreads and how much of a given job it can eventually reach. The authors build a unified framework that predicts roughly $2 trillion in long-run output gains, the loss of about 20 million American jobs, and falling prices.

The Supreme Court's decision in Trump v. Slaughter strips independent agencies of removal protections that made regulatory policy predictable across administrations. In new research, Brian Feinstein and Daniel Hemel find that equity markets assign real value to precisely that kind of insulation.